Durability of therapeutic response with long-term aripiprazole lauroxil treatment following successful resolution of an acute episode of Schizophrenia

Joseph P. McEvoy, Robert Risinger, Serhiy Mykhnyak, Yangchun Du, Chih Chin Liu, Arielle D. Stanford, Peter J. Weiden

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To evaluate durability of therapeutic effect of long-term treatment with aripiprazole lauroxil in patients with schizophrenia following successful treatment of an acute psychotic episode. Methods: This post hoc analysis assessed long-term outcomes for a subgroup of patients who entered a 52-week extension study after being successfully stabilized with one of 2 doses of aripiprazole lauroxil (441 or 882 mg) in a pivotal 12-week, placebo-controlled, randomized clinical trial. Durability of therapeutic effect was measured by the proportion of patients completing the 1-year course of aripiprazole lauroxil, the trajectories of the Positive and Negative Syndrome Scale (PANSS) total and the Clinical Global Impression-Severity (CGI-S) item scores beyond the first 12 weeks, and the likelihood of remission at any follow-up point. Results: In total, 181 patients treated with aripiprazole lauroxil entered the extension study; 73% and 66% of patients from the 441 mg and 882 mg groups, respectively, completed all 13 aripiprazole lauroxil treatments scheduled every 4 weeks over 52 weeks. Both groups continued on a positive trajectory of symptom improvements (P <.0001 for reductions in PANSS total and CGI-S scores from week 12 to end of follow-up). Most patients (74% and 68% in the aripiprazole lauroxil 441 mg and 882 mg groups, respectively) achieved remission during follow-up. Conclusions: These post hoc analyses of a subgroup of patients demonstrate the continued therapeutic efficacy of aripiprazole lauroxil after successful treatment of an acute episode of schizophrenia. Both the 441 mg and 882 mg groups had similar retention rates, degree of symptom improvement, and likelihood of remission.

Original languageEnglish (US)
Pages (from-to)1103-1109
Number of pages7
JournalJournal of Clinical Psychiatry
Volume78
Issue number8
DOIs
StatePublished - Sep 1 2017

Fingerprint

Schizophrenia
Therapeutic Uses
Therapeutics
aripiprazole lauroxil
Randomized Controlled Trials
Placebos

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Durability of therapeutic response with long-term aripiprazole lauroxil treatment following successful resolution of an acute episode of Schizophrenia. / McEvoy, Joseph P.; Risinger, Robert; Mykhnyak, Serhiy; Du, Yangchun; Liu, Chih Chin; Stanford, Arielle D.; Weiden, Peter J.

In: Journal of Clinical Psychiatry, Vol. 78, No. 8, 01.09.2017, p. 1103-1109.

Research output: Contribution to journalArticle

McEvoy, Joseph P. ; Risinger, Robert ; Mykhnyak, Serhiy ; Du, Yangchun ; Liu, Chih Chin ; Stanford, Arielle D. ; Weiden, Peter J. / Durability of therapeutic response with long-term aripiprazole lauroxil treatment following successful resolution of an acute episode of Schizophrenia. In: Journal of Clinical Psychiatry. 2017 ; Vol. 78, No. 8. pp. 1103-1109.
@article{c8a3c715b6384cf693dafb84e7abe024,
title = "Durability of therapeutic response with long-term aripiprazole lauroxil treatment following successful resolution of an acute episode of Schizophrenia",
abstract = "Objective: To evaluate durability of therapeutic effect of long-term treatment with aripiprazole lauroxil in patients with schizophrenia following successful treatment of an acute psychotic episode. Methods: This post hoc analysis assessed long-term outcomes for a subgroup of patients who entered a 52-week extension study after being successfully stabilized with one of 2 doses of aripiprazole lauroxil (441 or 882 mg) in a pivotal 12-week, placebo-controlled, randomized clinical trial. Durability of therapeutic effect was measured by the proportion of patients completing the 1-year course of aripiprazole lauroxil, the trajectories of the Positive and Negative Syndrome Scale (PANSS) total and the Clinical Global Impression-Severity (CGI-S) item scores beyond the first 12 weeks, and the likelihood of remission at any follow-up point. Results: In total, 181 patients treated with aripiprazole lauroxil entered the extension study; 73{\%} and 66{\%} of patients from the 441 mg and 882 mg groups, respectively, completed all 13 aripiprazole lauroxil treatments scheduled every 4 weeks over 52 weeks. Both groups continued on a positive trajectory of symptom improvements (P <.0001 for reductions in PANSS total and CGI-S scores from week 12 to end of follow-up). Most patients (74{\%} and 68{\%} in the aripiprazole lauroxil 441 mg and 882 mg groups, respectively) achieved remission during follow-up. Conclusions: These post hoc analyses of a subgroup of patients demonstrate the continued therapeutic efficacy of aripiprazole lauroxil after successful treatment of an acute episode of schizophrenia. Both the 441 mg and 882 mg groups had similar retention rates, degree of symptom improvement, and likelihood of remission.",
author = "McEvoy, {Joseph P.} and Robert Risinger and Serhiy Mykhnyak and Yangchun Du and Liu, {Chih Chin} and Stanford, {Arielle D.} and Weiden, {Peter J.}",
year = "2017",
month = "9",
day = "1",
doi = "10.4088/JCP.17m11625",
language = "English (US)",
volume = "78",
pages = "1103--1109",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "8",

}

TY - JOUR

T1 - Durability of therapeutic response with long-term aripiprazole lauroxil treatment following successful resolution of an acute episode of Schizophrenia

AU - McEvoy, Joseph P.

AU - Risinger, Robert

AU - Mykhnyak, Serhiy

AU - Du, Yangchun

AU - Liu, Chih Chin

AU - Stanford, Arielle D.

AU - Weiden, Peter J.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Objective: To evaluate durability of therapeutic effect of long-term treatment with aripiprazole lauroxil in patients with schizophrenia following successful treatment of an acute psychotic episode. Methods: This post hoc analysis assessed long-term outcomes for a subgroup of patients who entered a 52-week extension study after being successfully stabilized with one of 2 doses of aripiprazole lauroxil (441 or 882 mg) in a pivotal 12-week, placebo-controlled, randomized clinical trial. Durability of therapeutic effect was measured by the proportion of patients completing the 1-year course of aripiprazole lauroxil, the trajectories of the Positive and Negative Syndrome Scale (PANSS) total and the Clinical Global Impression-Severity (CGI-S) item scores beyond the first 12 weeks, and the likelihood of remission at any follow-up point. Results: In total, 181 patients treated with aripiprazole lauroxil entered the extension study; 73% and 66% of patients from the 441 mg and 882 mg groups, respectively, completed all 13 aripiprazole lauroxil treatments scheduled every 4 weeks over 52 weeks. Both groups continued on a positive trajectory of symptom improvements (P <.0001 for reductions in PANSS total and CGI-S scores from week 12 to end of follow-up). Most patients (74% and 68% in the aripiprazole lauroxil 441 mg and 882 mg groups, respectively) achieved remission during follow-up. Conclusions: These post hoc analyses of a subgroup of patients demonstrate the continued therapeutic efficacy of aripiprazole lauroxil after successful treatment of an acute episode of schizophrenia. Both the 441 mg and 882 mg groups had similar retention rates, degree of symptom improvement, and likelihood of remission.

AB - Objective: To evaluate durability of therapeutic effect of long-term treatment with aripiprazole lauroxil in patients with schizophrenia following successful treatment of an acute psychotic episode. Methods: This post hoc analysis assessed long-term outcomes for a subgroup of patients who entered a 52-week extension study after being successfully stabilized with one of 2 doses of aripiprazole lauroxil (441 or 882 mg) in a pivotal 12-week, placebo-controlled, randomized clinical trial. Durability of therapeutic effect was measured by the proportion of patients completing the 1-year course of aripiprazole lauroxil, the trajectories of the Positive and Negative Syndrome Scale (PANSS) total and the Clinical Global Impression-Severity (CGI-S) item scores beyond the first 12 weeks, and the likelihood of remission at any follow-up point. Results: In total, 181 patients treated with aripiprazole lauroxil entered the extension study; 73% and 66% of patients from the 441 mg and 882 mg groups, respectively, completed all 13 aripiprazole lauroxil treatments scheduled every 4 weeks over 52 weeks. Both groups continued on a positive trajectory of symptom improvements (P <.0001 for reductions in PANSS total and CGI-S scores from week 12 to end of follow-up). Most patients (74% and 68% in the aripiprazole lauroxil 441 mg and 882 mg groups, respectively) achieved remission during follow-up. Conclusions: These post hoc analyses of a subgroup of patients demonstrate the continued therapeutic efficacy of aripiprazole lauroxil after successful treatment of an acute episode of schizophrenia. Both the 441 mg and 882 mg groups had similar retention rates, degree of symptom improvement, and likelihood of remission.

UR - http://www.scopus.com/inward/record.url?scp=85032647363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032647363&partnerID=8YFLogxK

U2 - 10.4088/JCP.17m11625

DO - 10.4088/JCP.17m11625

M3 - Article

C2 - 28937706

AN - SCOPUS:85032647363

VL - 78

SP - 1103

EP - 1109

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 8

ER -